Consistently, upregulated pathways in cDCs from PI3K/mTORi+PD‐1i‐treated tumours were associated with antigen processing and presentation via MHC II, and positive regulation of T‐cell activation, suggesting enhanced antigen cross‐presentation, which is essential for T‐cell priming (Figure S5B). The gene discussed is PIK3CB; the disease is neoplasm.